Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 2/20 | 0.43 |
| ▸ | HTR2B | P41595 | 2/20 | 0.43 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.43 |
| ▸ | PTGER1 | P34995 | 6/20 | 0.41 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2104051 | 0.90 | SLC6A4 (0.44) | SLC6A4HTR2CHTR2BDGAT1PTGER1 | |
| SCHEMBL20805182 | 0.85 | DGAT1 (0.52) | HTR2BDGAT1 | |
| SCHEMBL25819319 | 0.85 | DGAT1 (0.44) | DGAT1PTGER1MRGPRX4 | |
| SCHEMBL9946168 | 0.83 | MAPT (0.49) | DGAT1 | |
| SCHEMBL24855370 | 0.82 | DGAT1 (0.41) | DGAT1PTGER1MEN1KMT2A | |
| SCHEMBL22712452 | 0.82 | DGAT1 (0.41) | SLC6A4HTR2CHTR2BDGAT1MRGPRX4 | |
| SCHEMBL31020087 | 0.81 | SLC6A4 (0.47) | SLC6A4HTR2CHTR2BDGAT1PTGER1 | |
| SCHEMBL24402681 | 0.81 | DGAT1 (0.42) | SLC6A4HTR2CHTR2BDGAT1MRGPRX4 | |
| SCHEMBL24855369 | 0.80 | PTGER1 (0.41) | DGAT1PTGER1MEN1KMT2A | |
| SCHEMBL30214788 | 0.80 | DGAT1 (0.45) | DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2952503-B1 | CARBOXYLIC ACID DERIVATIVES AS HIV REPLICATION INHIBITOR | SHIONOGI & CO (JP) | 2019-10-23 | — | — | EP | disclosed |
| US-20150361093-A1 | HIV REPLICATION INHIBITOR | SHIONOGI & CO., LTD. (JP) | 2015-12-17 | — | — | US | disclosed |
| US-20150361093-A1 | HIV REPLICATION INHIBITOR | SHIONOGI & CO., LTD. (JP) | 2015-12-17 | — | — | US | disclosed |
| EP-2952503-A1 | HIV REPLICATION INHIBITOR | Shionogi & Co., Ltd. (JP) | 2015-12-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150361093-A1 | HIV REPLICATION INHIBITOR | RTF2, REV1, PCNA | SLC6A4 2720/4885HTR2C 2238/4885HTR2B 1907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.